- Home
- BBUC vs IRON Comparison
BBUC vs IRON Comparison
Compare BBUC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBUC
- IRON
- Stock Information
- Founded
- BBUC 2022
- IRON 2017
- Country
- BBUC United States
- IRON United States
- Employees
- BBUC N/A
- IRON N/A
- Industry
- BBUC
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- BBUC
- IRON Health Care
- Exchange
- BBUC Nasdaq
- IRON Nasdaq
- Market Cap
- BBUC 2.2B
- IRON 2.0B
- IPO Year
- BBUC N/A
- IRON N/A
- Fundamental
- Price
- BBUC $33.00
- IRON $59.65
- Analyst Decision
- BBUC
- IRON Strong Buy
- Analyst Count
- BBUC 0
- IRON 11
- Target Price
- BBUC N/A
- IRON $95.73
- AVG Volume (30 Days)
- BBUC 92.5K
- IRON 307.9K
- Earning Date
- BBUC 08-01-2025
- IRON 08-07-2025
- Dividend Yield
- BBUC 0.76%
- IRON N/A
- EPS Growth
- BBUC N/A
- IRON N/A
- EPS
- BBUC N/A
- IRON N/A
- Revenue
- BBUC $8,240,000,000.00
- IRON N/A
- Revenue This Year
- BBUC N/A
- IRON N/A
- Revenue Next Year
- BBUC N/A
- IRON N/A
- P/E Ratio
- BBUC N/A
- IRON N/A
- Revenue Growth
- BBUC 6.96
- IRON N/A
- 52 Week Low
- BBUC $20.23
- IRON $30.82
- 52 Week High
- BBUC $35.19
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- BBUC 54.92
- IRON 53.58
- Support Level
- BBUC $28.29
- IRON $58.78
- Resistance Level
- BBUC $34.94
- IRON $61.05
- Average True Range (ATR)
- BBUC 0.97
- IRON 1.84
- MACD
- BBUC 0.23
- IRON -0.14
- Stochastic Oscillator
- BBUC 65.18
- IRON 28.88
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.